NCT04380337View on ClinicalTrials.gov

Organ Preservation Program Using Short-Course Radiation & FOLFOXIRI in Rectal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

May 21, 2020

Primary Completion Date

January 17, 2024

Study Completion Date

January 17, 2024

Conditions
Rectal Cancer
Interventions
DRUG

FOLFOXIRI

Chemotherapy regimen of Oxaliplatin 85mg/m2 , Leucovorin 400 mg/m2 , Irinotecan 165mg/m2 , 5-Fluorouracil

DRUG

FOLFOX regimen

Chemotherapy regimen of Oxaliplatin 85mg/m2, Leucovorin 400 mg/m2, 5-Fluorouracil 2400mg/m2

DRUG

XELOX

Chemotherapy regimen of Oxaliplatin 130 mg/m2, Capecitabine 1000mg/m2

RADIATION

IMRT

Radiotherapy (5 Gy x 5 fractions) with an additional boost fraction (5 Gy x 1 fraction) delivered sequentially

Trial Locations (1)

94304

Stanford University, Stanford

All Listed Sponsors
lead

Stanford University

OTHER

NCT04380337 - Organ Preservation Program Using Short-Course Radiation & FOLFOXIRI in Rectal Cancer | Biotech Hunter | Biotech Hunter